| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0862 |
| Trial ID | ChiCTR2000033480 |
| Disease | B-Cell Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | GB5005 |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Safety, tolerability, effectiveness and pharmacokinetics characteristic clinical research of intensive pretreatment combined with GB5005 chimeric antigen receptor T cell injection in the treatment of patients with CD19-positive relapsed / refractory B-cell non-Hodgkin's lymphoma (B-NHL) |
| Year | 2020 |
| Country | China |
| Company sponsor | Shanghai Zhaxin Hospital |
| Cohort 1 | |||||
|
|||||